Gemfibrozil Reduces Plasma Prothrombin Fragment F1+2 Concentration, a Marker of Coagulability, in Patients with Coronary Heart Disease

H Wilkes(Northwick Park Hospital), George J. Miller(Leiden University Medical Center), R D Rosenberg(Scripps Research Institute), Samuel Barzega, T W Meade(London School of Hygiene & Tropical Medicine), KA Bauer(University of Vermont), Liam O. Hughes(Norfolk and Norwich University Hospital), A J Foley(Medical Research Council)
Thrombosis and Haemostasis
January 1, 1992
10.1055/s-0038-1648481
Cited by 58

Related Papers

Randomized Trial of Preventive Angioplasty in Myocardial Infarction
|New England Journal of Medicine|2013|1k
Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data
|BMJ|2014|677
Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees.
|Journal of Clinical Investigation|1994|408
The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation
|Blood|1987|395
Cholesteryl Ester Transfer Protein TaqIB Variant, High-Density Lipoprotein Cholesterol Levels, Cardiovascular Risk, and Efficacy of Pravastatin Treatment
|Circulation|2005|310